In contrast, compared to buffer treated-VHL-KO control mice (day 3 vs. day 9 glucose levels, p = 0.040; Figure 6A, right panel), IGF-IR antagonist administration resulted in attenuation of hypoglycemia after tamoxifen injection (day 3 vs. day 9, p = 0.121: N.S.). The gene discussed is IGF1R; the disease is Hypoglycemia.